Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks
Portfolio Pulse from
Eli Lilly's Phase 3 SURMOUNT-1 study shows that tirzepatide significantly reduces the risk of progression to type 2 diabetes in adults with pre-diabetes and obesity or overweight. The study reports a 94% reduction in risk and an average weight reduction of 22.9% with the 15 mg dose over 176 weeks.
November 13, 2024 | 10:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's tirzepatide shows significant promise in reducing diabetes risk and promoting weight loss, as demonstrated in the SURMOUNT-1 study. This could enhance the company's market position in diabetes treatment.
The SURMOUNT-1 study results highlight tirzepatide's effectiveness in reducing diabetes risk and promoting weight loss, which could lead to increased demand and sales for Eli Lilly. This positive outcome is likely to boost investor confidence and positively impact LLY's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100